5-氟苯并呋喃-3(2H)-酮 | 60770-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-氟苯并呋喃-3(2H)-酮
• 中文别名: 5-氟-2,3-二氢-1-苯并呋喃-3-酮；5-氟-3-苯并呋喃酮
• 英文名称: 5-fluorobenzofuran-3(2H)-one
• 英文别名: 5-fluoro-1-benzofuran-3-one
• CAS: 60770-49-2
• 化学式: C₈H₅FO₂
• mdl: MFCD08544409
• 分子量: 152.125
• InChiKey: AOFLDWWKVCKMDV-UHFFFAOYSA-N

物化性质

• 熔点：
  >100°C (dec.)
• 溶解度：
  可溶于氯仿、DMSO（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Fluorobenzofuran-3-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Fluorobenzofuran-3-one
CAS number: 60770-49-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5FO2
Molecular weight: 152.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氟苯并呋喃-3(2H)-酮 在 potassium tert-butylate 、 氨 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 72.0h， 生成 3-(5-chloro-1-methyl-1H-indol-3-yl)-4-(5-fluorobenzofuran-3-yl)pyrrole-2,5-dione
  参考文献：
  名称：

  Structure-Based Design Leads to the Identification of Lithium Mimetics That Block Mania-like Effects in Rodents. Possible New GSK-3β Therapies for Bipolar Disorders

  摘要：

  More than two million American adults, or approximately one percent of the population 18 years or older, suffer from bipolar disorder. Current treatments include the so-called "mood stabilizers," lithium and valproic acid. Both are relatively dated drugs that are only partially effective and produce various undesirable side effects including weight gain. Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3 beta (GSK-3 beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders. Furthermore, the pro-apoptotic properties of the GSK-3 enzyme suggest the possible use of such inhibitors as neuroprotective agents. In fact, neuroprotection may contribute to the treatment of mood disorders. The present chemistry, modeling, and biology efforts have identified 3-benzofuranyl-4-indolylmaleimides as potent and relatively selective GSK-3 beta inhibitors. The best ligand in this series (having a K-i value of 4.6 nM against GSK-3 beta) was studied in a novel mouse model of mania that has recently been validated with several clinically effective mood stabilizers. This study presents the first demonstration of the efficacy of a GSK-3 beta inhibitor in this mouse model of mania. Selective brain penetrable GSK-3 ligands like those described herein become valuable research tools in better defining the role of this multifaceted kinase in both physiological and pathophysiological events.

  DOI：

  10.1021/ja068969w
• 作为产物：
  描述：

  2-ethynyl-4-fluoro-1-methoxybenzene 在 甲烷磺酸 、 8-isopropylquinoline N-oxide 、 BrettPhosAuNTf₂ 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 5.0h， 以68%的产率得到5-氟苯并呋喃-3(2H)-酮
  参考文献：
  名称：

  实用的，模块化的和一般的通过金催化的分子间炔烃氧化策略合成3-香豆酮的方法

  摘要：

  已经开发了一种金催化的分子间炔烃氧化方法，用于制备3-香豆素。使用8-异丙基喹啉N-氧化物作为氧化剂，邻乙炔基苯甲醚的反应可提供中等至良好的分离产率的多功能3-香豆醛酮。该化学方法的合成效用还通过天然产物硫酸脂的合成来表明。

  DOI：

  10.1002/asia.201403032

文献信息

• Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
  申请人：Asselin Magda

  公开号：US20070027160A1

  公开（公告）日：2007-02-01

  The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT 1A binding agents, particularly as 5-HT 1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.

  本发明涉及新型哌嗪-哌啶化合物。这些化合物可用作5-HT1A结合剂，特别是作为5-HT1A受体拮抗剂和激动剂。这些化合物在治疗中枢神经系统疾病方面很有用，如认知障碍、焦虑症、抑郁症和性功能障碍。
• [EN] OPIOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR OPIOÏDE
  申请人：UNIV COLUMBIA

  公开号：WO2016086158A1

  公开（公告）日：2016-06-02

  The present invention provides a compound having the structure wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, 0, or S; Y1 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 2 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y3 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 4 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y5 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); a and P are each present or absent and when present each is a bond.

  本发明提供了一种具有结构的化合物，其中A是一个环结构，带有或不带有取代基；X1是C或N；X2是N、O或S；Y1是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y2是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y3是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y4是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y5是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；a和P分别存在或不存在，当存在时，每个都是一个键。
• Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity
  作者：Aranapakam M. Venkatesan、O. Dos Santos、John Ellingboe、Deborah A. Evrard、Boyd L. Harrison、Deborah L. Smith、Rosemary Scerni、Geoffrey A. Hornby、Lee E. Schechter、Terrence H. Andree

  DOI：10.1016/j.bmcl.2009.12.093

  日期：2010.2

  Several benzofuran derivatives linked to a 3-indoletetrahydropyridine through an alkyl chain were prepared and evaluated for serotonin transporter and 5-HT1A receptor affinities. Their design, synthesis and structure–activity relationships are described.

  制备了几种通过烷基链与3-吲哚四氢吡啶连接的苯并呋喃衍生物，并评估了其血清素转运蛋白和5-HT 1A受体的亲和力。描述了它们的设计，合成和结构-活性关系。
• BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE
  申请人：Venkatesan Aranapakam Mudumbai

  公开号：US20090054454A1

  公开（公告）日：2009-02-26

  Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

  本专利揭示了苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这些化合物的组合物。还揭示了使用苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这种组合物在治疗和/或预防与5-羟色胺相关的疾病，如抑郁症和焦虑症的方法。此外，还揭示了制备苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物的方法。
• Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
  申请人：Venkatesan Mudumbai Aranapakam

  公开号：US20050004162A1

  公开（公告）日：2005-01-06

  3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.

  3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物已被披露。还披露了使用这些衍生物以及含有这些衍生物的组合物在预防和/或治疗血清素紊乱，如抑郁症和焦虑症方面的方法。此外，还披露了制备3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物的方法。